TapImmune signs new collaborative research agreement with VGTI Florida

Nov 18 2014

TapImmune, Inc. (OTCQB: TPIV), is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a leading, non-profit biomedical research institute, forming a partnership to advance TapImmune's proprietary, cancer vaccines into Phase II human clinical trials for the treatment of breast and ovarian cancers.

These highly promising therapeutic cancer vaccine candidates were developed by VGTI Florida's Director of Cancer Vaccines and Immune Therapies Program, Keith Knutson, Ph.D. The goal is to prevent breast and ovarian cancer recurrence for patients who achieve remissions following standard-of-care treatment. The vaccine works by enabling the immune system to target and eradicate any residual cancer cells or newly arising cancer cells that express the antigens delivered by the vaccine. TapImmune has already announced interim data on both clinical programs that exceeded its expectations for immune responses in the treated patients.

VGTI Florida will work with TapImmune to design and execute the Phase II clinical programs. This includes the design of the clinical protocols, selection of clinical trial sites, recruitment of key opinion leaders as clinical advisors, and selection of external manufacturing and clinical resources.

TapImmune had previously announced the licensing of these vaccines technologies for the treatment of HER2/neu breast cancer and ovarian and breast cancer developed in the laboratory of Dr. Keith Knutson while at the Mayo Clinic.

TapImmune's CEO, Glynn Wilson commented: "We are delighted to establish this collaboration with the Center for the Diseases of Aging at VGTI Florida to expand our relationship with Dr. Keith Knutson and leverage their unique experience in breast and ovarian cancer vaccine development and clinical trial design as we move our clinical programs into Phase II trials."